DexCom (DexCom) Other Stockholders Equity

: $0 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

DexCom's Other Stockholders Equity for the quarter that ended in Dec. 2023 was $0 Mil.

DexCom's annual Other Stockholders Equity declined from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) but then stayed the same from Dec. 2022 ($0 Mil) to Dec. 2023 ($0 Mil).

DexCom Other Stockholders Equity Historical Data

The historical data trend for DexCom's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

DexCom Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Stockholders Equity																-	-	-	-	-

DexCom Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

DexCom Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of DexCom's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

DexCom (DexCom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

DXCM:Mexico DC4:Germany DC4:Germany DC4:Germany DC4:Germany D1EX34:Brazil DXCM:Austria

Address

6340 Sequence Drive, San Diego, CA, USA, 92121

Website

https://www.dexcom.com

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Executives

Sadie Stern	officer: Chief Human Resources Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman	director
Kevin R Sayer	director
Jereme M Sylvain	officer: SVP, Finance & CAO	6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach	officer: SVP, Research & Development	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos	director	754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown	officer: EVP, Chief Legal Officer	6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli	officer: Vice President Legal Affairs	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan	officer: EVP Chief Technology Officer	C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan	officer: EVP Operations	1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller	director	TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan	officer: *	6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj	officer: SVP Information Technology	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn	officer: EVP, Global Revenue	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121